Dr. Robert Scott Venick, MD

Dr. Venick practices at Peter Morton UCLA Medical Building in Los Angeles, California.

Dr. Venick's NPI, 1235166075, was assigned on June 27, 2006. Dr. Venick graduated from Keck School of Medicine of USC in 2000. Dr. Venick's California license number on file is A77078.

Dr. Venick's primary practice is Peter Morton UCLA Medical Building, at 200 Medical Plz, Los Angeles, CA 90024 in Los Angeles County. The practice phone is (310) 794-9206.

Dr. Venick's primary practice is Peter Morton UCLA Medical Building in Los Angeles, California. Dr. Venick is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is Loma Linda University Faculty Medical Group (LLUFMG). Dmand AI also links Dr. Venick to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Venick practices, 3 sites in all. Vendor and product names are available with a free account.

Pediatric gastroenterology is Dr. Venick's primary specialty in the NPI Registry, under taxonomy code 2080P0206X. Dr. Venick is board certified in pediatric gastroenterology by the American Board of Pediatrics. Dr. Venick has a license on file in California.

CMS data shows 49 Medicare services from Dr. Venick across 1 procedure code in 2024, all of them office visits, for 23 Medicare patients. Medicare paid $5,332 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 23 Medicare patients who saw Dr. Venick in 2024. 52% of them have chronic kidney disease, and 48% have anxiety. Their average risk score is 5.09, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Venick's median patient age at 17, with 45% women.

In 2024, Dr. Venick wrote 28 Medicare Part D claims. 50% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $278 in total drug cost. In 2023, CMS named 12 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 78 out of 100 for Dr. Venick for performance year 2024, reported as part of a group. Dr. Venick accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Colonoscopy: 1 to 10 procedures (CMS shows small counts as a range)

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 26 papers to Dr. Venick, published from 2010 to 2025. 2013 was the busiest year, with 2. Dr. Venick's most frequent co-authors are Douglas G. Farmer, MD, Fady Michael Kaldas, MD and Reshma M. Biniwale, MD.

Dmand AI links Dr. Venick to 10 clinical trials, 3 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Short Bowel Syndrome, Hyperphagia and Cholestasis. Shire sponsors the most, 3.

CMS Open Payments shows 224 general payments to Dr. Venick from 12 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 66% of the total. Mirum Pharmaceuticals, Inc. paid the most, $55,887.

Dmand AI lists 2 awards for Dr. Venick, most recently Regional Top Doctor in 2014.

Dr. Venick graduated from Keck School of Medicine of USC in 2000.

Dr. Venick is in network with 15 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.